Drug Profile
KD 3010
Alternative Names: KD3010Latest Information Update: 24 Sep 2015
Price :
$50
*
At a glance
- Originator Kalypsys
- Class Antihyperglycaemics; Antihyperlipidaemics; Obesity therapies; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetes mellitus; Dyslipidaemias; Obesity
Most Recent Events
- 24 Sep 2015 No development reported - Phase-I for Obesity in USA (PO)
- 24 Sep 2015 No development reported - Preclinical for Diabetes mellitus in USA (PO)
- 24 Sep 2015 No development reported - Preclinical for Dyslipidaemias in USA (PO)